Role of diffusion-weighted imaging in response prediction and evaluation after high dose rate brachytherapy in patients with colorectal liver metastases.
HDR-brachytherapy
apparent diffusion coefficient
colorectal liver metastases
diffusion-weighted imaging
liver
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
10
11
2023
accepted:
04
01
2024
medline:
21
2
2024
pubmed:
21
2
2024
entrez:
20
2
2024
Statut:
epublish
Résumé
The aim of the study was to assess the role of diffusion-weighted imaging (DWI) to evaluate treatment response in patients with liver metastases of colorectal cancer. In this retrospective, observational cohort study, we included 19 patients with 18 responding metastases (R-Mets; follow-up at least one year) and 11 non-responding metastases (NR-Mets; local tumor recurrence within one year) who were treated with high-dose-rate brachytherapy (HDR-BT) and underwent pre- and post-interventional MRI. DWI (qualitatively, mean apparent diffusion coefficient [ADCmean], ADCmin, intraindividual change of ADCmean and ADCmin) were evaluated and compared between pre-interventional MRI, first follow-up after 3 months and second follow-up at the time of the local tumor recurrence (in NR-Mets, mean: 284 ± 122 d) or after 12 months (in R-Mets, mean: 387+/-64 d). Sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) for detection of local tumor recurrence were calculated on second follow up, evaluating (1) DWI images only, and (2) DWI with Gd-enhanced T1-weighted images on hepatobiliary phase (contrast-enhanced [CE] T1-weight [T1w] hepatobiliary phase [hb]). ADCmean significantly increased 3 months after HDR-BT in both groups (R-Mets: 1.48 ± 0.44 and NR-Mets: 1.49 ± 0.19 x 10 DW-MRI seems to be helpful in the qualitative and quantitative evaluation of treatment response after HDR-BT of colorectal metastases in the liver.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of the study was to assess the role of diffusion-weighted imaging (DWI) to evaluate treatment response in patients with liver metastases of colorectal cancer.
PATIENTS AND METHODS
METHODS
In this retrospective, observational cohort study, we included 19 patients with 18 responding metastases (R-Mets; follow-up at least one year) and 11 non-responding metastases (NR-Mets; local tumor recurrence within one year) who were treated with high-dose-rate brachytherapy (HDR-BT) and underwent pre- and post-interventional MRI. DWI (qualitatively, mean apparent diffusion coefficient [ADCmean], ADCmin, intraindividual change of ADCmean and ADCmin) were evaluated and compared between pre-interventional MRI, first follow-up after 3 months and second follow-up at the time of the local tumor recurrence (in NR-Mets, mean: 284 ± 122 d) or after 12 months (in R-Mets, mean: 387+/-64 d). Sensitivity, specificity, positive predictive values (PPVs), and negative predictive values (NPVs) for detection of local tumor recurrence were calculated on second follow up, evaluating (1) DWI images only, and (2) DWI with Gd-enhanced T1-weighted images on hepatobiliary phase (contrast-enhanced [CE] T1-weight [T1w] hepatobiliary phase [hb]).
RESULTS
RESULTS
ADCmean significantly increased 3 months after HDR-BT in both groups (R-Mets: 1.48 ± 0.44 and NR-Mets: 1.49 ± 0.19 x 10
CONCLUSIONS
CONCLUSIONS
DW-MRI seems to be helpful in the qualitative and quantitative evaluation of treatment response after HDR-BT of colorectal metastases in the liver.
Identifiants
pubmed: 38378033
pii: raon-2024-0017
doi: 10.2478/raon-2024-0017
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-42Informations de copyright
© 2024 Salma Karim et al., published by Sciendo.
Références
Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M, et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004; 58: 1496–505. doi: 10.1016/j.ijrobp.2003.09.024
doi: 10.1016/j.ijrobp.2003.09.024
Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 2004; 15: 1279–86. doi: 10.1097/01.Rvi.0000141343.43441.06
doi: 10.1097/01.Rvi.0000141343.43441.06
Seidensticker M, Wust P, Rühl R, Mohnike K, Pech M, Wieners G, et al. Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases. Radiat Oncol 2010; 5: 24. doi: 10.1186/1748-717x-5-24
doi: 10.1186/1748-717x-5-24
Ricke J, Mohnike K, Pech M, Seidensticker M, Rühl R, Wieners G, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479–85. doi: 10.1016/j.ijrobp.2009.09.026
doi: 10.1016/j.ijrobp.2009.09.026
Wybranski C, Zeile M, Löwenthal D, Fischbach F, Pech M, Röhl FW, et al. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases. Radiat Oncol 2011; 6: 43. doi: 10.1186/1748-717x-6-43
doi: 10.1186/1748-717x-6-43
Bretschneider T, Ricke J, Gebauer B, Streitparth F. Image-guided high-dose-rate brachytherapy of malignancies in various inner organs − technique, indications, and perspectives. J Contemp Brachytherapy 2016; 8: 251–61. doi: 10.5114/jcb.2016.61068
doi: 10.5114/jcb.2016.61068
Omari J, Drewes R, Orthmer M, Hass P, Pech M, Powerski M. Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, inter-stitial brachytherapy as second-line or salvage therapy. Diagn IntervRradiol 2019; 25: 360–7. doi: 10.5152/dir.2019.18390
doi: 10.5152/dir.2019.18390
Chow DH, Sinn LH, Ng KK, Lam CM, Yuen J, Fan ST, et al. Radiofrequency ablation for hepatocellular carcinoma and metastatic liver tumors: a comparative study. J Surg Oncol 2006; 94: 565–71. doi: 10.1002/jso.20674
doi: 10.1002/jso.20674
Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992; 1 59: 591–9. doi: 10.2214/ajr.159.3.1503032
doi: 10.2214/ajr.159.3.1503032
Dudeck O, Zeile M, Wybranski C, Schulmeister A, Fischbach F, Pech M, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol 2010; 20: 2699–706. doi: 10.1007/s00330-010-1846-z
doi: 10.1007/s00330-010-1846-z
Welsh JS, Kennedy AS, Thomadsen B. Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66(2 Suppl): S62–73. doi: 10.1016/j.ijrobp.2005.09.011
doi: 10.1016/j.ijrobp.2005.09.011
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60. doi: 10.1055/s-0030-1247132
doi: 10.1055/s-0030-1247132
Kim MN, Kim BK, Han KH, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Rev Gastroenterol Hepatol 2015; 9: 335–48. doi: 10.1586/17474124.2015.959929
doi: 10.1586/17474124.2015.959929
Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, et al. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: imaging analysis from a prospective randomized trial of Y90 ± Sorafenib. Hepatology 2013; 58: 1655–66. doi: 10.1002/hep.26487
doi: 10.1002/hep.26487
Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol 2006; 9: 125–32. doi: 10.1053/j.tvir.2007.02.004
doi: 10.1053/j.tvir.2007.02.004
Ludwig JM, Camacho JC, Kokabi N, Xing M, Kim HS. The role of diffusion-weighted imaging (DWI) in Locoregional therapy outcome prediction and response assessment for hepatocellular carcinoma (HCC): the new era of functional imaging biomarkers. Diagnostics 2015; 5: 546–63. doi: 10.3390/diagnostics5040546
doi: 10.3390/diagnostics5040546
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47. doi: 10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026
Hamm B, Thoeni RF, Gould RG, Bernardino ME, Lüning M, Saini S, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994; 190: 417–23. doi: 10.1148/radiology.190.2.8284392
doi: 10.1148/radiology.190.2.8284392
Ishida K, Tamura A, Kato K, Uesugi N, Osakabe M, Eizuka M, et al. Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy. Abdom Radiol (NY) 2018; 43: 2991–3000. doi: 10.1007/s00261-018-1588-y
doi: 10.1007/s00261-018-1588-y
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622–35. doi: 10.2214/ajr.06.1403
doi: 10.2214/ajr.06.1403
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and per-fusion in neurologic disorders. Radiology 1986; 161: 401–7. doi: 10.1148/radiology.161.2.3763909
doi: 10.1148/radiology.161.2.3763909
Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894–900. doi: 10.1148/radiol.2483071407
doi: 10.1148/radiol.2483071407
Eccles CL, Haider EA, Haider MA, Fung S, Lockwood G, Dawson LA. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol 2009; 48: 1034–43. doi: 10.1080/02841860903099972
doi: 10.1080/02841860903099972
Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001–8. doi: 10.2214/ajr.06.0601
doi: 10.2214/ajr.06.0601
Marugami N, Tanaka T, Kitano S, Hirohashi S, Nishiofuku H, Takahashi A, et al. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc Intervent Radiol 2009; 32: 638–46. doi: 10.1007/s00270-009-9532-8
doi: 10.1007/s00270-009-9532-8
Schraml C, Schwenzer NF, Clasen S, Rempp HJ, Martirosian P, Claussen CD, et al. Navigator respiratory-triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 2009; 29: 1308–16. doi: 10.1002/jmri.21770
doi: 10.1002/jmri.21770
Schmeel FC, Simon B, Luetkens JA, Traber F, Meyer C, Schmeel LC, et al. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. J Cancer Res Clin Oncol 2017; 143: 1531–41. doi: 10.1007/s00432-017-2395-5
doi: 10.1007/s00432-017-2395-5
Lahrsow M, Albrecht MH, Bickford MW, Vogl TJ. Predicting treatment response of colorectal cancer liver metastases to conventional lipiodol-based transarterial chemoembolization using diffusion-weighted MR imaging: value of pretreatment apparent diffusion coefficients (ADC) and ADC changes under therapy. Cardiovasc Intervent Radiol 2017; 40: 852–9. doi: 10.1007/s00270-017-1634-0
doi: 10.1007/s00270-017-1634-0
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–9. doi: 10.1016/j.jclinepi.2007.11.008
doi: 10.1016/j.jclinepi.2007.11.008
Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010; 78: 172–9. doi: 10.1016/j.ijrobp.2009.07.1700
doi: 10.1016/j.ijrobp.2009.07.1700
Ingenerf MK, Karim H, Fink N, Ilhan H, Ricke J, Treitl KM, et al. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol 2022; 63: 877–88. doi: 10.1177/02841851211024004
doi: 10.1177/02841851211024004
Outwater E, Tomaszewski JE, Daly JM, Kressel HY. Hepatic colorectal metastases: correlation of MR imaging and pathologic appearance. Radiology 1991; 180: 327–32. doi: 10.1148/radiology.180.2.2068294
doi: 10.1148/radiology.180.2.2068294
Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RG. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging 2012; 35: 1365–71. doi: 10.1002/jmri.23589
doi: 10.1002/jmri.23589
Liu Z, Fan JM, He C, Li ZF, Xu YS, Li Z, et al. Utility of diffusion weighted imaging with the quantitative apparent diffusion coefficient in diagnosing residual or recurrent hepatocellular carcinoma after transarterial chemoembolization: a meta-analysis. Cancer Imaging 2020; 20: 3. doi: 10.1186/s40644-019-0282-9
doi: 10.1186/s40644-019-0282-9